PTC Therapeutics
PTCT
155 hedge funds and large institutions have $1.57B invested in PTC Therapeutics in 2015 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 84 increasing their positions, 31 reducing their positions, and 33 closing their positions.
171% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 33
1% less funds holding
Funds holding: 157 → 155 (-2)
18% less capital invested
Capital invested by funds: $1.92B → $1.57B (-$340M)
18% less call options, than puts
Call options by funds: $35.3M | Put options by funds: $43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$74.2M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$36.1M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$34.8M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$33.2M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$19.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$139M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$64.3M |
| 3 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$35.8M |
| 4 |
YCMGA
York Capital Management Global Advisors
New York
|
-$21.9M |
| 5 |
JCI
Jet Capital Investors
New York
|
-$18.9M |
PTCT Hedge Fund Activity: Q2 2015 in Review
155 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2015, worth a combined $1.57B — down 18% from $1.92B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of PTCT and 31 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 84 added.
The largest buyer was Waddell & Reed Financial, opening a new position worth an estimated $74.2M. The largest seller was Fidelity Investments, cutting an estimated $139M.
- 155 institutional investors held PTC Therapeutics (PTCT) as of Q2 2015, down from 157 in Q1 2015.
- Funds reported $1.57B of PTC Therapeutics stock for Q2 2015, down 18% quarter-over-quarter.
- 31 funds opened new PTC Therapeutics positions in Q2 2015 and 33 closed out, a net change of -2 holders.
- The largest PTC Therapeutics buyer in Q2 2015 was Waddell & Reed Financial, an estimated $74.2M added.
- The largest PTC Therapeutics seller in Q2 2015 was Fidelity Investments, an estimated $139M sold.
Based on aggregated 13F filings for Q2 2015.